ArticleAACE endocrinology and diabetes
Galactorrhea and Pituitary Microadenoma in an 18-Year-Old Transfeminine Youth: A Case Report.
Article in AACE endocrinology and diabetes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objective: Gender-affirming hormone therapy (GAHT) improves psychological well-being in transfeminine individuals but may cause endocrine alterations, including hyperprolactinemia and, rarely, pituitary adenomas. We report the youngest known case of galactorrhea and pituitary microadenoma associated with unsupervised GAHT, highlighting multifactorial contributing factors. Case Report: An 18-year-old transfeminine youth presented with galactorrhea while taking self-administered GAHT without medical supervision. Laboratory testing showed elevated prolactin, and magnetic resonance imaging revealed a pituitary microadenoma. Contributing factors included high-dose estradiol, cyproterone acetate, concomitant antiretroviral and antidepressant therapy, and frequent breast massage. Discussion: This case highlights the endocrine vulnerability of adolescents using unsupervised GAHT. The combined effects of estrogen excess, antiandrogen therapy, serotonergic and dopaminergic modulation, and mechanical breast stimulation likely contributed to hyperprolactinemia. Limited pediatric data and lack of structured hormonal monitoring delayed diagnosis and optimal management. Multidisciplinary care integrating endocrine follow-up and mental health support is essential to ensure treatment safety. Conclusion: Unsupervised GAHT in adolescents can lead to significant endocrine complications through multifactorial mechanisms. Early recognition, structured monitoring, and coordinated multidisciplinary care are crucial to balance gender-affirming goals with patient safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.